Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial. - Wander SA; Lloyd MR; Keenan JC; Scott EC; Niemierko A; Spring LM; Fell GG; Shin J; Isakoff SJ; Moy B; Ryan L; Padden S; et al. (The Lancet. Oncology, 2026)